1988
DOI: 10.1007/bf00175398
|View full text |Cite
|
Sign up to set email alerts
|

Phase I — Preliminary phase II trial of iproplatin, a cisplatin analogue

Abstract: Iproplatin was administered intravenously over 30 min daily for 5 consecutive days every 3 weeks to 80 evaluable patients with a variety of refractory solid tumor malignancies. Thrombocytopenia was the dose-limiting toxicity. Reversible drug-induced renal dysfunction was observed in 3 patients. One patient sustained mild ototoxicity but neurotoxicity was not encountered. Transient neutropenia, anemia, nausea, vomiting, diarrhea, elevations of liver enzymes, alopecia, and skin rash also occurred. The spectrum a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

1992
1992
2023
2023

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(3 citation statements)
references
References 7 publications
0
3
0
Order By: Relevance
“…The same study recommended intravenous doses of 324 mg m –2 over 2 h every 3–4 weeks for Phase II trials in children. Other studies proposed doses of 45–65 and 95 mg m –2 for patients treated on a five-times daily schedule every 3 weeks and a four-times weekly schedule with two-week break periods, respectively . Phase II trials were carried out in patients with a variety of different cancer types. Phase III trials were conducted in ovarian cancer patients and those with metastatic epidermoid carcinoma of the head and neck. , The ultimate conclusion of these studies was that iproplatin did not exhibit overall effectiveness that surpassed that of cisplatin or carboplatin, and no further trials were undertaken.…”
Section: Platinum(iv) Prodrugs That Release Classical Platinum(ii) An...mentioning
confidence: 99%
See 1 more Smart Citation
“…The same study recommended intravenous doses of 324 mg m –2 over 2 h every 3–4 weeks for Phase II trials in children. Other studies proposed doses of 45–65 and 95 mg m –2 for patients treated on a five-times daily schedule every 3 weeks and a four-times weekly schedule with two-week break periods, respectively . Phase II trials were carried out in patients with a variety of different cancer types. Phase III trials were conducted in ovarian cancer patients and those with metastatic epidermoid carcinoma of the head and neck. , The ultimate conclusion of these studies was that iproplatin did not exhibit overall effectiveness that surpassed that of cisplatin or carboplatin, and no further trials were undertaken.…”
Section: Platinum(iv) Prodrugs That Release Classical Platinum(ii) An...mentioning
confidence: 99%
“…Other studies proposed doses of 45−65 and 95 mg m −2 for patients treated on a five-times daily schedule every 3 weeks and a four-times weekly schedule with two-week break periods, respectively. 336 Phase II trials were carried out in patients with a variety of different cancer types. 337−341 Phase III trials were conducted in ovarian cancer patients and those with metastatic epidermoid carcinoma of the head and neck.…”
Section: Platinum(iv) Prodrugs That Release Classical Platinum(ii) An...mentioning
confidence: 99%
“…The same study recommended intravenous doses of 324 mg·m −2 over 2 h every 3–4 weeks for Phase II trials in children. Other studies proposed doses of 45–65 mg·m −2 and 95 mg·m −2 for patients treated on a five-times-daily schedule every three weeks and a four-times-weekly schedule with two-week break periods, respectively [ 83 ]. Phase II trials were carried out in patients with a variety of different cancer types, and Phase III trials were conducted in ovarian cancer patients and those with metastatic epidermoid carcinoma of the head and neck [ 84 , 85 ].…”
Section: New Metallo-drugs In Clinical Trialsmentioning
confidence: 99%